RxDoctor Payments Data

Michael Drabkin, MD

Vascular & Interventional Radiology · East Meadow, NYNPI 1992048391

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,780 of the $17,443 with a category attached, or 84.7%. Medical Device Business Services, Inc. accounts for 79.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $7,571 and has fallen 97.0% since, to $230 in 2025.

$17,443in general payments, 2019–2025

Across 70 payments — averaging $249.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$14K
  • Terumo Medical Corporation$3K
  • Johnson & Johnson$591
  • Bard Peripheral Vascular, Inc.$192
  • Merit Medical Systems Inc$109
  • AstraZeneca$75
  • plus $190 from 6 others

What the payments were for

  • Consulting fees$14,78085%
  • Travel & lodging$9926%
  • Food & beverage$1,5969%
  • Education$750%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,443 in reported general payments places this provider in the 80th percentile of 306 vascular & interventional radiology providers in New York.

See all vascular & interventional radiology providers in New York

Medicare billing

Part B allowed, 2024
$2,497,268
Medicare patients
903
Services billed
6,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylprednisolone193$1,339
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$803
Ciprofloxacin Hcl136$649
Naproxen132$301
Oxybutynin Chloride29$178
Ondansetron OdtOndansetron14$156
Ondansetron Hcl18$97

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in East Meadow

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →